Health Technology
Novartis Pharma AG | September 19, 2022
Sandoz, a global leader in off-patent medicines, announces further progress on its biosimilar pipeline, with the release of positive results from the integrated ROSALIA Phase I/III clinical trial study for its proposed biosimilar denosumab.
“Biosimilars have the opportunity to create a substantial positive impact on patient access and healthcare systems sustainability. Therefore, this important milestone means that we are one step closer to giving individ...
Read More